Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells

Anti-Cancer Drugs

Volumn 14, Issue 4, 2003, Pages 281-287

  Bélanger, Martin M ^a   Roussel, Élise ^a   Couet, Jacques ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Caveolae; Caveolin; Cytotoxic drug; Multidrug resistance

Indexed keywords

CAVEOLIN; CAVEOLIN 1; CAVEOLIN 2; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; PACLITAXEL;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CAVEOLIN 1; CAVEOLIN 2; CAVEOLINS; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; IMMUNOBLOTTING; PACLITAXEL; RNA, MESSENGER; UP-REGULATION;

EID: 0037568199     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200304000-00005     Document Type: Article

References (28)

1. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998; 273:32380-32383.
2. Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 1998; 439:368-372.
3. Couet J, Li S, Okamoto T, Scherer PE, Lisanti MP. Molecular and cellular biology of caveolae: paradox and plasticities. Trends Cardiovasc Med 1997; 7:103-110.
4. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J Biol Chem 1998; 273:5419-5422.
5. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain (CSD) Implications for the interaction of caveolin with caveolin-associated proteins. J Biol Chem 1997; 272:6525-6533.
6. Li S, Couet J, Lisanti MP. Src tyrosine kinases, Gα subunits and H-Ras share a common membrane-anchored scaffolding protein, Caveolin. J Biol Chem 1996; 271:29182-29190.
7. Sager R, Sheng S, Anisowicz A, et al. RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harbor Sym Quant Biol 1996; LIX:537-546.
8. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin-1 gene expression in lung cancer cell lines. Biochem Biophys Res Commun 1999; 255:580-586.
9. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998; 16:1391-1397.
10. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 1999; 96:14517-14522.
11. Bangma CH, Nasu Y, Ren C, Thompson TC. Metastasis-related genes in prostate cancer. Semin Oncol 1999; 26:422-427.
12. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999; 35:664-671.
13. Thompson TC. Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev 1998; 17:439-442.
14. Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, et al. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 1999; 18:1881-1890.
15. Pflug DR, Reiter RE, Nelson JB. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 1999; 40:269-273.
16. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998; 4:1062-1064.
17. Demeule M, Jodoin J, Gingras D, Beliveau R. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 2000; 466:219-224.
18. Fielding CJ, Bist A, Fielding PE. Intracellular cholesterol transport in synchronized human skin fibroblasts. Biochemistry 1999; 38:2506-2513.
19. Caamano J, Ruggeri B, Momiki S, Sickler A, Zhang SY, Klein-Szanto AJ. Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol 1991; 139:839-845.
20. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt M, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5:1079-1088.
21. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998; 17:6633-6648.
22. Engelman JA, Chu C, Lin A, et al. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 1998; 428:205-211.
23. Engelman JA, Zhang XL, Razani B, Pestell RG, Lisanti MP. p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J Biol Chem 1999; 274:32333-32341.
24. Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998; 273:32111-32120.
25. Galbiati F, Volonte D, Engelman JA, Scherer PE, Lisanti MP. Targeted downregulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation. J Biol Chem 1999; 274:30315-30321.
26. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265:808-811.
27. Sanchez-Perez I, Perona R. Lack of c-Jun activity increases survival to cisplatin. FEBS Lett 1999; 453:151-158.
28. 2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 1996; 271:30950-30955.